Headquartered in Paris, GFBiochemicals is a leading sustainable chemical company with a mission to end chemical pollution. It provides companies that make our everyday products with safe, sustainable solvents and ingredients derived from the biobased levulinic molecule. This has three benefits: it ensures that everyday products are biodegradable, non-harmful and carbon friendly. GFBiochemicals has offices and R&D facilities in the Netherlands and the United States, operations in India, and over 200 active patents across 40 patent families. Through a Joint Venture, NXTLEVVEL, the company leverages proprietary technology to enable commercial-scale manufacturing of products.
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.